Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double‐blind, placebo‐controlled study. Issue 3 (31st July 2014)

• Record Type: Journal Article
• Authors: Kashiwagi, A.; Kazuta, K.; Goto, K.; Yoshida, S.; Ueyama, E.; Utsuno, A.
• Is Part Of: Diabetes, obesity & metabolism. Volume 17:Issue 3(2015:Mar.)
• Page Start: 304
• Page End: 308
• Publication Date: 2014-07-31
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12331
• Languages: English
• ISSNs: 1462-8902

Abstract

<abstract abstract-type="main" id="dom12331-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p id="dom12331-para-0001">This multicenter, double‐blind, placebo‐controlled study examined the efficacy and safety of ipragliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in combination with metformin in Japanese patients with type 2 diabetes mellitus (T2DM). Patients were randomized in a 2 : 1 ratio to 50 mg ipragliflozin (n = 112) or placebo (n = 56) once daily for 24 weeks, followed by a 28‐week open‐label extension in which all patients received 50 or 100 mg ipragliflozin, while continuing metformin. The primary outcome was the change in glycated haemoglobin (HbA1c) from baseline to week 24. HbA1c decreased significantly in the ipragliflozin group (−0.87%; adjusted mean difference from placebo: −1.30%; p &lt; 0.001). The overall incidence of treatment‐emergent adverse events was similar in both groups, although pollakiuria and constipation were more common in the ipragliflozin group; thus, ipragliflozin significantly improved glycaemic control and reduced body weight without major safety issues in Japanese patients with T2DM.</p> </abstract>